{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Crespo-Leiro MG"],"funding":["CareDx Inc"],"pagination":["2591-601"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC5015661"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["37(33)"],"pubmed_abstract":["<h4>Aims</h4>A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II), was conducted to further clinically validate the GEP test performance.<h4>Methods and results</h4>Blood samples for GEP testing (AlloMap(®), CareDx, Brisbane, CA, USA) were collected during post-transplant surveillance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive values (PPVs) for the GEP scores (range 0-39) were computed. Considering the GEP score of 34 as a cut-"],"journal":["European heart journal"],"pubmed_title":["Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II."],"pmcid":["PMC5015661"],"funding_grant_id":["NCT00761787"],"pubmed_authors":["Mohacsi P","Deng MC","Parameshwar J","Schulz U","Fiocchi R","Zuckermann A","Crespo-Leiro MG","Elashoff B","Yee JP","Stypmann J","Leprince P","Colvin M","Hoefer D","Ross H","Vanhaecke J","Zakliczynski M","Bara C"],"additional_accession":[]},"is_claimable":false,"name":"Clinical usefulness of gene-expression profile to rule out acute rejection after heart transplantation: CARGO II.","description":"<h4>Aims</h4>A non-invasive gene-expression profiling (GEP) test for rejection surveillance of heart transplant recipients originated in the USA. A European-based study, Cardiac Allograft Rejection Gene Expression Observational II Study (CARGO II), was conducted to further clinically validate the GEP test performance.<h4>Methods and results</h4>Blood samples for GEP testing (AlloMap(®), CareDx, Brisbane, CA, USA) were collected during post-transplant surveillance. The reference standard for rejection status was based on histopathology grading of tissue from endomyocardial biopsy. The area under the receiver operating characteristic curve (AUC-ROC), negative (NPVs), and positive predictive values (PPVs) for the GEP scores (range 0-39) were computed. Considering the GEP score of 34 as a cut-","dates":{"release":"2016-01-01T00:00:00Z","publication":"2016 Sep","modification":"2026-04-07T19:12:37.066Z","creation":"2019-03-26T23:06:41Z"},"accession":"S-EPMC5015661","cross_references":{"pubmed":["26746629"],"doi":["10.1093/eurheartj/ehv682"]}}